威爾明頓，特拉華州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- 創新驅動的醫療技術成長型公司 Enovis™ Corporation （NYSE: ENOV，以下簡稱「Enovis」或「公司」）今日宣布已完成對 LimaCorporate S.p.A （以下簡稱「Lima」）的收購。Lima 是一家私人控股的全球骨科領先企業，專注於透過創新的植入解決方案組合恢復運動功能。 Lima 憑藉成熟的手術解決方案和技術的互補性產品組合，鞏固了 Enovis 在全球骨科重建市場的地位，這將加速公司的全球增長和利潤擴張。此外，Lima 的產品組合包括 3D 打印 Trabecular Titanium 植入物和全面的肩部修復產品，這將進一步加強該公司在快速成長的四肢市場中的地位。 「我們很高興歡迎 Lima 的優秀團隊加入 Enovis。此次合併使 Enovis 的重建分部收入達到 10 億美元，並成為全球骨科重建市場快速成長的創新者。這是我們如何利用策略性收購來加速成長、為公司增添優秀技術和人才、以及為股東帶來複合價值的又一範例。」Enovis 董事長兼行政總裁 Matt Trerotol ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 (State or other jurisdiction of incorporation or organization) Delaware 54-1887631 (I.R.S. Employer Identification No.) 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 (Address of principal executive offices) (Zip Code) OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to_______ Commission file number 001-34045 _________________________ ENOVIS CORPORATION (Exact name of registrant as specified in its charter) S ...

Financial Data and Key Metrics Changes - The company reported a 15% growth in organic revenue and a 32% increase in adjusted EPS for Q3 2021, despite a challenging environment [7][46] - Total company EBITDA margins grew by 20 basis points, with a 90 basis point improvement before the effect from acquisitions [45] Business Line Data and Key Metrics Changes - ESAB exceeded expectations with a 24% increase in total sales, driven by high single-digit volume growth and a 15-point price increase [36] - MedTech sales increased by 40%, with organic sales per day growth of 1%, impacted by a 2-point headwind from one-time sales in Q3 last year [11][50] Market Data and Key Metrics Changes - In the Americas, ESAB volumes rose by 11%, while EMEA and APAC increased by 6% compared to the same period last year [37] - The MedTech business experienced a 14% growth over Q3 2020, with organic sales per day growth of 3% excluding PPE [50] Company Strategy and Development Direction - The company is on track for a tax-free spin-off of its ESAB business, targeting separation in Q1 2022, with substantial progress in creating independent boards and filling key leadership positions [10][30] - The new corporate name, Enovis, symbolizes a strategic pivot to a specialty MedTech company focused on innovative solutions [29][30] Management's Comments on Operating Environment and Future Outlook - Management noted that the recovery of elective surgeries is expected to improve gradually, with a potential for market growth in the coming years as backlogged procedures are addressed [72][74] - The company anticipates continued operational improvements and margin expansion, despite challenges from supply chain inflation and inefficiencies [16][100] Other Important Information - The company is implementing price increases to offset inflation and expects sequential margin improvement in Q4 [17][56] - The integration of recent acquisitions is progressing well, with expectations for significant revenue growth and cost synergies [25][28] Q&A Session Summary Question: What steps are left to complete the split? - Management indicated that they are well into the process, with key leadership positions filled and capital structure aligned, expecting no significant challenges [60] Question: How is the MedTech recovery expected to progress? - Management noted a 5% pressure on elective surgeries due to COVID, but they anticipate gradual improvement and a return to normal levels in 2022 [72][74] Question: What is the pricing strategy in MedTech? - Management explained that pricing can be passed through in some areas, while others depend on reimbursement rates, which may take time to adjust [63][117] Question: How are supply chain issues being managed? - Management highlighted the use of CBS tools to improve customer service and manage supply chain challenges effectively [78] Question: What are the growth expectations for the MedTech business? - Management expects the recon business to grow in healthy double digits, while the P&R business is positioned to grow at or above market rates [111][112]